Aikaterini Chatzidionysiou

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713

Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.

Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: LUPUS. 2024;33(6):615-628

Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey

Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: MICROBIOLOGY SPECTRUM. 2024;12(4):e0298123-e02923

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)

Frodlund M; Nived P; Chatzidionysiou K; Soedergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
Article: RMD OPEN. 2023;9(4):e003648

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

Bower H; Frisell T; di Giuseppe D; Delcoigne B; Lindstrom U; Turesson C; Chatzidionysiou K; Lindqvist E; Knight A; Forsblad-d'Elia H; Askling J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52(6):591-600

Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic

Karlsson M-L; Hertzberg-Nyquist K; Saevarsdottir S; Lundberg IE; Demmelmaier I; Pettersson S; Chatzidionysiou K
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2023;41(10):1985-1990

Original research on Behçet's syndrome: a bibliometric analysis over 20 years (2000-2019)

Bolla E; Chatzidionysiou K; Tektonidou MG; Sfikakis PP
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(16):5377

Intracardiac Thrombi in Morbus Adamantiades-Behcet in Two Swedish Patients

Da Mutten R; Borg A; Chatzidionysiou K; Parodis I
Article: VACCINE. 2023;41(20):3247-3257

The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)

Frodlund M; Nived P; Chatzidionysiou A; Sodergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
Article: PLOS ONE. 2023;18(12):e0295838

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: RHEUMATOLOGY. 2022;61(10):3952-3962

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data

Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindstrom U; Turesson C; Frisell T
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022;56:152050

Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis.

Yang C; Williams RD; Swerdel JN; Almeida JR; Brouwer ES; Burn E; Carmona L; Chatzidionysiou K; Duarte-Salles T; Fakhouri W; Hottgenroth A; Jani M; Kolde R; Kors JA; Kullamaa L; Lane J; Marinier K; Michel A; Stewart HM; Prats-Uribe A; Reisberg S; Sena AG; Torre CO; Verhamme K; Vizcaya D; Weaver J; Ryan P; Prieto-Alhambra D; Rijnbeek PR
Article: RMD OPEN. 2022;8(2):e002465

Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking

Chatzidionysiou K; di Giuseppe D; Soderling J; Catrina A; Askling J
Article: RHEUMATOLOGY. 2022;61(9):3647-3656

The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries

Di Giuseppe D; Lindstrom U; Aaltonen K; Relas H; Provan S; Gudbjornsson B; Hetland ML; Askling J; Kauppi M; Geirsson AJ; Chatzidionysiou K; Jorgensen TS; Dreyer L; Michelsen B; Jacobsson L; Glintborg B
Article: RHEUMATOLOGY. 2022;61(9):3596-3605

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden

Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjowall C; Lindqvist E; Askling J
Article: CRITICAL REVIEWS IN IMMUNOLOGY. 2022;42(4):21-36

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.

Flores-Chávez A; Brito-Zerón P; Retamozo S; Bitoun S; Fisher BA; Liew D; Suijkerbuijk K; Chatzidionysiou K; Suárez-Almazor M; Lambotte O; Mariette X; Ramos-Casals M
Article: RMD OPEN. 2021;7(3):e001987

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

Bower H; Frisell T; di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(10):1512-1518

Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis

Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(8):1086-1093

Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study

Bower H; Frisell T; Di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: RMD OPEN. 2021;7(2):e001662

Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL

Chatzidionysiou K; Circiumaru A; Rethi B; Joshua V; Engstrom M; Hensvold A; af Klint E; Catrina A
Article: RHEUMATOLOGY. 2021;60(2):820-828

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg J-E; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordstrom DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 2):247-252

The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.

Koutsianas C; Chatzidionysiou K
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2020;38(5):841-847

Validation of new classification criteria of rheumatoid arthritis in an international multicentre study

Li R; Sun X; Ye H; Liu J; Zhao J; Liu X; Mei Y; Zhang Z; Guo J; Bi L; Wang G; Leng X; Gu F; Sun L; Zou Q; Fang Y; Jiang Q; Chatzidionysiou K; Priya S; Janardana R; Nair A; Catrine AI; Danda D; Li ZG
Article: RMD OPEN. 2020;6(2):e001278

Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis

Joshua V; Hensvold AH; Reynisdottir G; Hansson M; Cornillet M; Nogueira L; Serre G; Nyren S; Karimi R; Eklund A; Skold M; Grunewald J; Chatzidionysiou K; Catrina A
Article: RMD OPEN. 2020;6(2):e001363

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordstrom D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
Article: RMD OPEN. 2020;6(2):e001183

Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study.

Najm A; Alunno A; Sivera F; Ramiro S; Haines C; Working Group on Training in Rheumatology across E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus

Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: ARTHRITIS RESEARCH & THERAPY. 2020;22(1):56

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

Panopoulos S; Chatzidionysiou K; Tektonidou MG; Bournia VK; Drosos AA; Liossis S-NC; Dimitroulas T; Sakkas L; Boumpas D; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Sidiropoulos P; Bertsias G; Vassilopoulos D; Sfikakis PP
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):1-2

Mediterranean Journal of Rheumatology March 2020 Highlights.

Chatzidionysiou K
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):87-91

Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.

Adamichou C; Flouri I; Fanouriakis A; Nikoloudaki M; Nikolopoulos D; Repa A; Boki K; Chatzidionysiou K; Garyfallos A; Boumpas D; Sidiropoulos P; Bertsias G
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20976975-1759720X2097697

Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus

Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis PP; Tektonidou MG
Article: RHEUMATOLOGY. 2019;58(12):2170-2176

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus

Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173

Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials

Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: JOURNAL OF DIABETES RESEARCH. 2019;2019:2936962-8

Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy

Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies

Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration

Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordstrom D; Canhao H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(6):465-474

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries

Glintborg B; Lindstrom U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MRK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140

Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial

Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2018;5(1):e000287

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort

Giannakou I; Chatzidionysiou K; Magder LS; Gyori N; van Vollenhoven R; Petri MA
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration

Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordstrom D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Victoria Hernandez M; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2017;4(1):e000192

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.

Györi N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):314

Differences and similarities in rheumatology speciality training programmes across European countries (vol 74, pg 1183, 2015)

Sivera F; Ramiro S; Cikes N
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):213

Rheumatology training experience across Europe: analysis of core competences

Sivera F; Ramiro S; Cikes N; Cutolo M; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(sup128):64-75

Optimizing biological treatments for rheumatoid arthritis

Chatzidionysiou K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study

Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; Lukina G; Nordstrom DC; Lie E; Ancuta I; Victoria Hernandez M; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(2):230-236

Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Article: RMD OPEN. 2016;2(1):e000133

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Cöster L; Forslind K; van Vollenhoven R; Heimbürger M
Article: RMD OPEN. 2016;2(2):e000323

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.

Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437

Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register

Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1183-1187

Differences and similarities in rheumatology specialty training programmes across European countries

Sivera F; Ramiro S; Cikes N; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R
Journal article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2013;102(3):233-241

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.

Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
Journal article: CLINICAL PRACTICE. 2013;10(3):233-236

Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?

Chatzidionysiou K; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

Chatzidionysiou K; van Vollenhoven RF
Article: LANCET. 2012;379(9827):1712-1720

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: BMJ OPEN. 2012;2(5):e001524

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study

Kastbom A; Coster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapaa-Dahlqvist S; Saevarsdottir S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1822-1825

Delays in assessment of patients with rheumatoid arthritis: variations across Europe

Raza K; Stack R; Kumar K; Filer A; Detert J; Bastian H; Burmester GR; Sidiropoulos P; Kteniadaki E; Repa A; Saxne T; Turesson C; Mann H; Vencovsky J; Catrina A; Chatzidionysiou A; Hensvold A; Rantapaa-Dahlqvist S; Binder A; Machold K; Kwiakowska B; Ciurea A; Tamborrini G; Kyburz D; Buckley CD
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam SA; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF
Article: LANCET. 2009;374(9688):459-466

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Coster L; Waltbrand E; Zickert A; Theander J; Thorner A; Hellstrom H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wornert M; Bratt J
Visa fler

Alla övriga publikationer

Conference publication: ANNALS OF ONCOLOGY. 2023;34:s688-s689

Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)

Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1164.1-111165

AN UNUSUAL INITIAL PRESENTATION OF VEXAS SYNDROME

Galindo-Feria AS; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:856

SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Sebbag E; Molina Collada J; Lauper K; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:2053-2054

RISK FACTORS FOR DEVELOPING RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS AFTER IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS

Liapi M; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:863

SERONEGATIVE RHEUMATOID ARTHRITIS (RA) - IS IT REALLY RA?

Wettersand EB; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:533.1-53533

THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE SEROLOGICAL IMMUNOGENICITY FOLLOWING THREE DOSES OF COVID-19 VACCINE AND PERSISTENCE OF IMMUNOGENICITY OF TWO VACCINE DOSES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - A SWEDISH STUDY (COVID19-REUMA)

Frodlund M; Nived P; Chatzidionysiou K; Sodergren A; Klingberg E; Hansson M; Pin E; Klareskog L; Kapetanovic MC
Review: RMD OPEN. 2023;9(1):e002898

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

van der Togt CJT; van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:29

EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Sebbag E; Lauper K; Collada JM; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Review: ANNALS OF THE RHEUMATIC DISEASES. 2023;82(1):3-18

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Smolen JS; Landewe RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg J-E; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e140

Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al.

Bettiol A; Pregnolato F; Sciascia S; Emmi G; Prisco D; Meroni PL
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e141

Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al

Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:1017

TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-INDUCED INFLAMMATORY ARTHRITIS AND POLYMYALGIA RHEUMATICA

Liapi M; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:588

RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: RESULTS FROM AN INTERNATIONAL DELPHI STUDY

Van der Togt C; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaacs J; Mulleman D; Verschueren P; Vulto A; Welsing P; Verhoef LM; Den Broeder A
Review: BIOMEDICINE & PHARMACOTHERAPY. 2022;148:112687

Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy

Jensen AK; Chatzidionysiou K; Torp CK; Sorensen AS; Tenstad HB; Schafer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Editorial comment: FRONTIERS IN MEDICINE. 2022;9:1020859

Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases.

Md Yusof MY; Alivernini S; Chatzidionysiou K
Review: LAKARTIDNINGEN. 2021;118:21114

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].

Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Corrigendum: JOURNAL OF DIABETES RESEARCH. 2021;2021:9827150-1

Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy (vol 2019, 2936962, 2019)

Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Review: CLINICAL RHEUMATOLOGY. 2021;40(5):1687-1695

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 1):120-128

Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium.

Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:762-763

SIMILAR CARDIOVASCULAR COMORBIDITY AND HIGHER DEPRESSION RATES IN PSORIATIC ARTHRITIS COMPARED TO AGE- AND SEX-MATCHED RHEUMATOID ARTHRITIS AND DIABETES MELLITUS PATIENTS

Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis P; Tektonidou M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1004.1-101004

COMPARATIVE RISK OF CANCER ASSOCIATED WITH FIRST-LINE DMARDS USE IN RHEUMATOID ARTHRITIS: REAL WORLD EVIDENCE FROM THE OHDSI NETWORK

Duarte-Salles T; Recalde M; Weaver J; Burn E; Marinier K; Diaz Y; Illingens B; Vizcaya D; Chatzidionysiou K; Ryan P; Prieto-Alhambra D
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:134.2-13134

DEVELOPMENT AND VALIDATION OF PATIENT-LEVEL PREDICTION MODELS FOR ADVERSE HEALTH OUTCOMES AMONGST ADULT RA PATIENTS INITIATING FIRST-LINE TREATMENT OF METHOTREXATE MONOTHERAPY: A MULTINATIONAL REAL-WORLD COHORT ANALYSIS INCLUDING 164,735 SUBJECTS

Yang C; Williams R; Swerdel J; Jani M; Duarte-Salles T; Chatzidionysiou K; Prieto-Alhambra D; Ryan P; Rijnbeek P
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:331.1-33331

FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES

Sena AG; Granados D; Hughes N; Fakhouri W; Hottgenroth A; Kolde R; Reisberg S; Torre CO; Duarte-Salles T; Diaz Y; Golib-Dzib JF; Brouwer ES; Burn E; Lane J; Vizcaya D; Wirta SB; De Wilde M; Verhamme K; Rijnbeek P; Theander E; Chatzidionysiou K; Prieto-Alhambra D; Ryan P
Letter: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000415

Could severe COVID-19 be considered a complementopathy?

Chatzidionysiou K; Svenungsson E; Faustini F
Review: CLINICAL RHEUMATOLOGY. 2020;39(3):957-961

Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?

Fragoulis GE; Chatzidionysiou K
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(2):304-307

Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus

Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Review: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2019;33(5):101476

Established rheumatoid arthritis - Redefining the concept

Chatzidionysiou K; Fragoulis GE
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus

Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2019;30(2):103-109

Rheumatic disease and artistic creativity.

Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:1800.1-181800

ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE

Panopoulos S; Tektonidou M; Chatzidionysiou K; Drosos A; Liossis S-N; Dimitroulas T; Sakkas L; Boumpas D; Sidiropoulos P; Bertsias G; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Vassilopoulos D; Sfikakis P
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:703-704

EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND RITUXIMAB) AFTER FAILURE OF NON-TNFI BIOLOGIC DMARD IN RHEUMATOID ARTHRITIS - COLLABORATION BETWEEN FIVE NATIONAL REGISTERS

Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Trokovic N; Kristianslund E; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782

ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761

PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Corrigendum: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(3):258

Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients (vol 48, pg 178, 2019)

Glintborg B; Lindstrom U; Aaltonen K; Kristianslund E; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland M; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MEK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Review: RMD OPEN. 2019;5(2):e000993

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift

Chatzidionysiou K; Sfikakis PP
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:891

SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB

Chatzidionysiou K; Engstrom M; af Klint E; Hensvold A; Catrina AI
Review: ANNALS OF THE RHEUMATIC DISEASES. 2018;77(4):476-479

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis

Radner H; Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich KL; Zabalan C; van Eijk-Hustings Y; Williamson PR; Balanescu A; Burmester GR; Carmona L; Dougados M; Finckh A; Haugeberg G; Hetland ML; Oliver S; Porter D; Raza K; Ryan P; Santos MJ; van der Helm-van Mil A; van Riel P; von Krause G; Zavada J; Dixon WG; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:A39-A40

SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB

Chatzidionysiou K; Engstrom M; Af Klint E; Hensvold A; Catrina AI
Corrigendum: RMD OPEN. 2018;4(1)

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)

Chatzidionysiou K; Hetland ML; Frisell T
Corrigendum: RMD OPEN. 2018;4(1):rmdopen-2018-000655corr1

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)

Chatzidionysiou K; Hetland ML; Frisell T
Review: RMD OPEN. 2018;4(1):e000655

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example

Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Tormanen MRK; Kristianslund EK; Kvien TK; Provan SA; Guobjornsson B; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson L; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:69-70

PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS - RESULTS FROM THE HOPKINS LUPUS COHORT

Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:1027

HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS

Chatzidionysiou K; Aaltonen K; Nordstrom D; Gudbjornsson B; Grondal G; Geirsson AJ; Steingrimsdottir L; Frisell T; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:567

DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?

Finckh A; Courvoisier D; Gottenberg J-E; Marlette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kviens TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:517-518

DETERMINING MINIMUM CLINICALLY IMPORTANT CHANGE IN MULTI BIOMARKER DISEASE ACTIVITY SCORE ASSOCIATED WITH CLINICAL IMPROVEMENT IN METHOTREXATE NAIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

Chatzidionysiou K; Hensvold AH; Saevarsdottir S; Bolce RJ; Chernoff D; Hwang CC; Wang X; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:686

PRESCRIPTION PATTERNS OF TUMOUR NECROSIS FACTOR INHIBITOR AND USTEKINUMAB IN PSORIATIC ARTHRITIS: A NORDIC POPULATION-BASED COHORT STUDY

Jorgensen TS; Dreyer L; Gudbjornsson B; Hetland ML; Glintborg B; Askling J; Chatzidionysiou K; Di Giuseppe D; Jacobsson L; Wallman JK; Kristianslund EK; Olsen IC; Fagerli K; Lie E; Nordstrom D; Aaltonen K; Joensuu J; Love TJ; Geirsson AJ; Kristensen LE
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:341-342

PRESCRIPTION PATTERNS OF BIOLOGICAL DISEASE MODIFYING DRUGS AND BIOSIMILARS IN ANKYLOSING SPONDYLITIS - A COLLABORATION BETWEEN BIOLOGICAL REGISTERS IN THE FIVE NORDIC COUNTRIES

Glintborg B; Chatzidionysiou K; Askling J; Aaltonen K; Kristianslund E; Gudbjornsson B; Nordstrom D; Hetland ML; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Kvien T; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Jacobsson L
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):960-977

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Smolen JS; Landewe R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg J-E; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poor G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1102-1107

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis

Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1101-1136

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewe RBM
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1113-1136

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewe R
Conference publication: SWISS MEDICAL WEEKLY. 2017;147:3S

Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-TNF mode of action?

Finckh A; Courvoisier DS; Gottenberg J-E; Mariette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Review: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):251

Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature

Nikiphorou E; Radner H; Chatzidionysiou K; Desthieux C; Zabalan C; van Eijk-Hustings Y; Dixon WG; Hyrich KL; Askling J; Gossec L
Corrigendum: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):144

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (vol 18, 50, 2016)

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:166

THE EULAR TASK FORCE FOR STANDARDISING MINIMUM DATA COLLECTION IN RHEUMATOID ARTHRITIS OBSERVATIONAL RESEARCH: RESULTS OF A HIERARCHICAL LITERATURE REVIEW

Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J; Radner H
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477-478

ASSOCIATION BETWEEN NUMBER AND TYPE OF DIFFERENT ACPA FINE SPECIFICITIES AND PARENCHYMAL LUNG CHANGES IN HIGH RESOLUTION COMPUTED TOMOGRAPHY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

Joshua V; Chatzidionysiou K; Reynisdottir G; Hensvold AH; Hansson M; Nogueira L; Eklund A; Serre G; Grunewald J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:299-300

RELATIONSHIP BETWEEN CORTICOSTEROIDS AND UNFAVORABLE MEDICAL EFFECTS. A STUDY UNDER THE SHARE SYSTEM BASED ON THE CLINICAL TRIAL BELIMUMAB IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (BLISS-76)

Emamikia S; Gentline C; Backheden M; Chatzidionysiou K; Arnaud L; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477

RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY

Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina A
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:499

INDUCTION-MAINTENANCE IN EARLY RA: A META-ANALYSIS OF TRIALS USING MTX PLUS TNF-INHIBITOR AS INDUCTION THERAPY

Emamikia S; Arkema EV; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:406-407

TOWARDS DEVELOPMENT OF A MINIMUM CORE DATASET AND STANDARDS OF DATA COLLECTION FOR OBSERVATIONAL RHEUMATOID ARTHRITIS RESEARCH A EULAR INITIATIVE

Radner H; Nikiphorou E; Chatzidionysiou K; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J
Corrigendum: CURRENT OPINION IN RHEUMATOLOGY. 2016;28(2):1

The lung in rheumatoid arthritis, cause or consequence? Erratum.
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:A79

RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY

Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:484-485

SMOKING AND RESPONSE TO RITUXIMAB IN ANTI-CCP POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS - RESULTS FROM AN INTERNATIONAL EUROPEAN COLLABORATION

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Hauge E; Pavelka K; Gabay C; Nordstrom D; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Ancuta I; Kvien T; van Vollenhoven R; Saevarsdottir S
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:798-799

DISEASE ACTIVITY PATTERNS OVER TIME IN PATIENTS WITH SLE - A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF THE HOPKINS LUPUS COHORT

Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:492

RITUXIMAB DONE! WHAT'S NEXT IN RHEUMATOID ARTHRITIS? A EUROPEAN OBSERVATIONAL LONGITUDINAL STUDY ASSESSING THE EFFECTIVENESS OF BIOLOGICS AFTER RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS

Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S65-S66

Disease activity patterns over time in patients with SLE - A retrospective descriptive analysis of the Hopkins Lupus Cohort

Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:601-602

RETENTION OF TOCILIZUMAB THERAPY: A COMPARISON BETWEEN TOCILIZUMAB IN MONOTHERAPY AND IN COMBINATION WITH DMARDS BASED ON THE TOCERRA COLLABORATION

Gabay C; Riek M; Hetland M; Hauge EM; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; van Vollenhoven R; Lukina G; Nordstrom D; Lie E; Ancuta I; Loza Santamaria E; van Riel P; Kvien T
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:674

EFFECTIVENESS OF REPEATED COURSES OF RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:505-506

FIXED VERSUS ON-FLARE RETREATMENT WITH RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Thesis / dissertation: 2014

Biological therapy in rheumatoid arthritis : epidemiological studies

Chatzidionysiou, Katerina
Editorial comment: NATURE REVIEWS RHEUMATOLOGY. 2013;9(9):510-512

RHEUMATOID ARTHRITIS Triple therapy or etanercept after methotrexate failure in RA?

van Vollenhoven RF; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:517-518

TREATMENT WITH CERTOLIZUMAB PEGOL IN RA - DATA FROM THE NATIONAL REGISTRY ARTIS (ANTIRHEUMATIC THERAPIES IN SWEDEN)

Chatzidionysiou K; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:182

SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:62

EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:A14-U75

EFFICACY OF TNF SWITCH AFTER FAILURE OF ONE TNF INHIBITOR - RESULTS FROM A NATION-WIDE OBSERVATIONAL STUDY

Chatzidionysiou K; Eriksson J; Askling J; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:a13-A14

EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION

Chatzidionysiou K; Lie E; Nasonov EL; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLC; Gomez-Reino JJ; Kvien TK; van Vollenhoven RF
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(6):614-625

When to initiate and discontinue biologic treatments for rheumatoid arthritis?

Chatzidionysiou K; van Vollenhoven RF
Visa fler

Forskningsbidrag

Optimal Treatment of Early Rheumatoid Arthritis: The NORD-STAR randomized trial embedded in the Swedish Rheumatology Quality Register SRQ: Combining Pragmatic Trials and National Registers...

Swedish Research Council

1 January 2015 - 31 December 2017

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, reumatologi, Karolinska Institutet, 2020
Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2014

Handledare

Marie-Louise Karlsson, The impact of lifestyle changes, and treatment adherence in Early Rheumatoid Arthritis, 2023

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Handledare

Nyheter från KI

Kalenderhändelser från KI